|
| Authors | Animal model | Allotransplant model | MSC source | Combined short-term immunosuppressant | Outcome |
|
| Kuo et al. (2009) [53] | Swine | Hind-limb VCA
(allogeneic) | Donor bone marrow | CsA | MSC alone, prolong allograft survival; MSC + TBI + BMT + CsA, significantly prolong graft survival |
|
| Pan et al. (2010) [61] | Rat | Hind-limb VCA
(allogeneic) | Allogeneic bone marrow | Rapamycin + ALG | MSC + rapamycin + ALG + TBI + BMT prolong allograft survival and induce mixed chimerism |
|
| Kuo et al. (2011) [35] | Swine | Hind-limb VCA
(allogeneic) | Donor bone marrow | CsA | MSC + CsA + TBI prolong allograft survival |
|
| Kuo et al. (2011) [34] | Rat | Hind-limb VCA
(allogeneic) | Allogeneic adipose tissue | ALS + CsA | MSC + ALS + CsA prolong allograft survival and induce immune tolerance |
|
| Kuo et al. (2012) [66] | Swine | Facial VCA
(allogeneic) | Donor bone marrow | CsA | MSC + CsA prolong allograft survival |
|
| Itakura et al. (2007) [65] | Rat | Islet cell transplant
(allogeneic) | Allogeneic bone
marrow | CsA | MSC + BMT + CsA prolong islet allograft survival and induce immune tolerance |
|
| Kim et al. (2011) [43] | Rat | Islet cell transplant
(allogeneic) | Autologous bone
marrow | CsA | Prolong islet allograft survival |
|
| Casiraghi et al. (2008) [64] | Mouse | Heart
(semiallogeneic) | Donor allogeneic bone marrow | — | Prolong heart allograft survival |
|
| Ge et al. (2009) [67] | Mouse | Heart
(allogeneic) | Donor allogeneic bone marrow | Rapamycin | Prolong heart allograft survival |
|
| Sbano et al. (2008) [60] | Rat | Alloskin transplantation
(allogeneic) | Donor allogeneic bone marrow | CsA | MSC + CsA prolong skin allograft survival |
|
